Menu
Search
|

Menu

Close
X

BeyondSpring Inc BYSI.OQ (NASDAQ Stock Exchange Capital Market)

25.00 USD
-0.88 (-3.40%)
As of Jul 17
chart
Previous Close 25.88
Open 26.15
Volume 3,210
3m Avg Volume 4,405
Today’s High 26.30
Today’s Low 24.80
52 Week High 42.67
52 Week Low 19.55
Shares Outstanding (mil) 22.46
Market Capitalization (mil) 583.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.766
FY17
-4.943
FY16
-0.403
FY15
-0.229
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
--
8.04
Price to Book (MRQ)
vs sector
33.30
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.25
Return on Investment (TTM)
vs sector
-175.01
13.23
Return on Equity (TTM)
vs sector
-161.81
15.27

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

28 Liberty St Fl 39
NEW YORK   NY   10005-1451

Phone: +1646.5284184
Site:

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

SPONSORED STORIES